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doi:10.1016/j.kjms.2011.10.017Abstract To evaluate the competitive potential of a new lipophilic paramagnetic complex, Gd-
Bz-TTDA [4-benzyl-3,6,10-tri (carboxymethyl)-3,6,10-triazado-decanedioic acid] compared with
two other commercially available MR hepatobiliary contrast agents, gadobenate dimeglumine
(Gd-BOPTA) and gadoxetic acid (Gd-EOB-DTPA), dynamic MR imaging studies were performed
on normal and hepatocellular carcinoma (HCC) rat models using a 1.5-Tesla MR scanner. The
results indicate that normal rats that were injectedwith 0.1mmol/kg Gd-Bz-TTDA showed signif-
icantly more intense and persistent liver enhancement than those that were injected with the
same dose of Gd-EOB-DTPA or Gd-BOPTA. All of these agents showed similar enhancement
patterns in the implanted HCC. The liver-lesion contrast-to-noise ratios were higher and more
persistent in rats that were injected with Gd-Bz-TTDA. These results indicate that Gd-Bz-
TTDA is comparable with the commercially available hepatobiliary agents, Gd-EOB-DTPA and
Gd-BOPTA, and can result in more intense and prolonged liver enhancement while still providing
better liver-lesion discrimination. These results warrant further large-scale studies.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.t of Medical Imaging, Kaoh-
Tz-You 1st Road, Kaohsiung,
(T.-S. Jaw).
vier Taiwan LLC. All rights reservIntroduction
In recent years, three hepatobiliary-specific contrast
agentsdmangafodipir trisodium (Mn-DPDP, Teslascan, GE
Healthcare, Oslo, Norway), gadobenate dimeglumine (Gd-
BOPTA, MultiHance, Bracco, Milan, Italy) and gadoxetic acid
(Gd-EOB-DTPA, Primovist, Bayer, Berlin, Germany)dhaveed.
Gd-Bz-TTDA, Gd-EOB-DTPA, BOPTA in rat liver MRI 131been become clinically available for use in magnetic reso-
nance imaging (MRI) [1]. The two gadolium-based agents are
able to initially distribute throughout the extracellular fluid
spaces as an extracellular contrast agents and are subse-
quently and selectively taken up by the hepatocytes [1e3].
These contrast agents have proven their usefulness for
improving lesion detection in MR imaging of the liver, as well
as for characterizing the hepatocellular and non-
hepatocellular properties of liver tumors [1,2,4e7].
We have developed and characterized a new lipophilic
paramagnetic complex, Gd-Bz-TTDA [4-benzyl-3,6,10-tri
(carboxymethyl)-3,6,10-triazado-decanedioic acid], which
was designed for use as hepatic MR contrast agent [8,9].
The preliminary results of our previous study showed
intense liver enhancement in normal rats lasting from
5 minutes to 3 hours. Gd-Bz-TTDA can also improve tumor
conspicuity in late phase images by providing intense liver
enhancement [10]. A toxicity study was also conducted that
shows that it is safe for these purposes [10]. The R1
relaxivity of Gd-Bz-TTDA is superior to Gd-BOPTA. Its
rotational correlation time is longer than Gd-EOB-DTPA,
and its water-exchange lifetime is significantly shorter
than Gd-EOB-DTPA and Gd-BOPTA [8,9]. To evaluate the
competitive potential of this novel contrast agent against
Gd-EOB-DTPA and Gd-BOPTA, dynamic MR imaging studies
of the livers of normal rats and rats with implanted HCC
were performed using these three agents.
Materials and methods
Study design
For the MR imaging studies, 12 normal male Wister rats
(National Laboratory Animal Breeding and Research Center,
Taipei, Taiwan) were used, each weighing 200e250 g. Three
rats were randomly assigned to each group. At each MR
scan, three rats were immobilized on the same polystyrene
board after being anesthetized. Each group received
intravenous injection of 0.1 mmol/kg Gd-Bz-TTDA, Gd-EOB-
DTPA, or Gd-BOPTA respectively. A marker was adminis-
tered to each rat, and the type of contrast agent that was
given was recorded. During the next study, which occurred
at least 3 days later, each rat received a different contrast
agent that was administered in the first study. During the
third MR imaging study, which also occurred at least for 3
days later, each rat received the remaining contrast agent
that they had not received in either of the two previous
studies. A total of six rats with implanted HCC (Cheng
hepatoma ascites [CHA], AS 30-D; Academia Sinica, Taipei,
Taiwan) were also studied. MR imaging studies of the rats
with HCC used a similar experimental design as that
described above.
Animal models
The CHA hepatoma model [11] was successfully conducted
by percutaneously injecting 0.25 mL (107e108 cells/mL) of
the CHA suspension into six Wistar rats. A CHA hepatoma
usually takes 1e3 weeks to reach its predetermined size.
The experiment was performed 3 weeks after implantation,
when the tumors measured at least 1 cm in diameter.MR imaging
The rats were anesthetized with an intraperitoneal injec-
tion of sodium pentobarbital at a dose of 40e50 mg/kg. The
tail veins were cannulated using a 1-mL disposable syringe
filled with the contrasting agent. The rats were then placed
in a head coil in the prone position. MR imaging was per-
formed using a 1.5-T superconductive MR scanner (Gyroscan
ACS-NT; Philips Medical Systems, Best, Netherlands). T1-
and T2-weighted coronal spin echo (SE) images were
acquired as the baseline images. Sequential T1-weighted
turbo field-echo (TFE) (TR/TE/flip angle: 15 msec/6.1
msec/25) coronal images were obtained before and after
intravenous injection of the contrasting agents. The
following parameters were used: number of excitations,
two; field of view, 20 cm; slice thickness, 4 mm; and image
matrix, 256  128. To assess any dynamic changes in
enhancement, postcontrast scans were obtained every
14 seconds for nine continuous scans, every 5 minutes for
six subsequent scans, and every 10 minutes for up to
2 hours. Similar protocols with additional T2-weighted
images were used on the rats with implanted HCC, both
before and after the intravenous injection one of the three
contrast agents. During scanning, a glass cylinder contain-
ing 2% weight/volume agarose gel was positioned adjacent
to the rats as a reference standard.
Image analysis
Operator-defined regions of interest were selected for the
liver parenchyma, away from vessels or artifacts, and from
the agarose gel reference standard. Approximately 0.1 cm2
was used for the regions of interest in the liver and the solid
and necrotic compartments of the tumors. The operator
was blind to information regarding which contrast agents
had been injected into the individual rats.
MR images were analyzed in order to evaluate any time-
enhancement changes that occurred in the livers of the
normal rats that could be identified using the three contrast
agents. The signal intensity of each target was normalized by
dividing itsmean target-signal intensity by thatof theagarose
gel standard (signal-to-noise ratio, SI/N). The enhancement
percentage of the liver was calculated as follows:
Enhancement %Z
ðSI=NÞtðSI=NÞpre
ðSI=NÞDre
 100%
In this equation, (SI/N)t and (SI/N)pre are the post-
contrast and precontrast signal-to-noise ratios of the liver,
respectively. The enhancement percentages at different
time points were compared for each contrast agent. Results
are expressed as the mean  SD. The Student t test was
used to compare differences between two of the three
groups. A p-value <0.05 was considered statistically
significant. Lesion conspicuity was assessed by the
percentage increase in the liver-lesion contrast-to-noise
ratio (CNR) using the following formula:
% Increase of Liver-Lesion CNR
Z
½ðSIliver  SIlesionÞ=Nt½ðSIliver  SIlesionÞ=Npre
½ðSIliver  SIlesionÞ=Npre
 100%
Table 1 The liver enhancement (%) in normal rats during
various phases after injection of 0.1 mmol/kg Gd-Bz-TTDA,
Gd-EOB-DTPA, or Gd-BOPTA.
Phases Bz-TTDA EOB-DTPA BOPTA
Arterial (28 sec) 82.9  23.4 86.2  20.0 80.5  15.2
Venous (70 sec) 124.8  28.4 136.9  28.3 111.6  33.5
Equilibrium
(126 sec)
138.5  31.0 139.2  32.7 115.7  33.4
Hepatobiliary
5 min 151.0  40.5* 150.2  32.7* 115.3  35.8
30 min 125.6  21.6** 78.7  28.5 74.3  30.6
60 min 117.4  27.3** 48.9  12.4 47.2  23.1
120 min 110.8  30.9** 17.9  11.0 25.6  9.5
(mean  standard deviation, n Z 12 in each group).
* p < 0.05: Bz-TTDA vs. BOPTA at 5 minutes; EOB-DTPA vs.
BOPTA at 5 minutes.
** p < 0.001: Bz-TTDA vs. EOB-DTPA; Bz-TTDA vs BOPTA at 30,
60, and 120 minutes.
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were assessed separately as the percentage of increase in
liver-lesion CNR.
Histopathological confirmation
The rats with implanted HCC were sacrificed immediately
after the last MR scan by cardiac exsanguinations under
deep anesthesia with ether. The livers implanted with HCC
were removed and fixed in 10% formalin following autopsy.
Paraffin-embedded sections and eosin-stained preparations
were microscopically observed to determine the presence
of HCC.
Results
The time-enhancement changes that occurred in the
normal rats after being injected with 0.1 mmol/kg Gd-Bz-
TTDA, Gd-EOB-DTPA or Gd-BOPTA are shown in Fig. 1. Liver
enhancement in the normal rats rose rapidly during the first
5 minutes in each group. After that, liver enhancement
plateaued in the Gd-Bz-TTDA group, then steadily but
slowly declined over the next 2 hours. Liver enhancement
in normal rats injected with Gd-EOB-DTPA or Gd-BOPTA
peaked at 5 minutes after injection, then gradually
declined. At 10 minutes and thereafter, Gd-Bz-TTDA
produced significantly better liver enhancement than Gd-
EOB-DTPA and Gd-BOPTA. (At 10 minutes, Gd-Bz-TTDA
[152.3  26.3%] vs. Gd-EOB-DTPA [130.5  22.8%],
p < 0.05; Gd-Bz-TTDA vs. Gd-BOPTA [106.7  22.7%];
p < 0.001) (Fig. 1). As shown in Table 1, there are no
statistical differences in the percentages of liver
enhancement measured in each of the three group during
the arterial, venous, or equilibrium phases. At 5 minutes,
there were significantly higher percentages of liver
enhancement in the Gd-Bz-TTDA and Gd-EOB-DTPA groups
compared with the Gd-BOPTA group (p < 0.05). Gd-Bz-TTDA
produced significantly more intense enhancement in liver
than the other two groups at each time point after 30
minutes (p < 0.001) (Table 1).
The livers of the normal rats that were injected with Gd-
Bz-TTDA, Gd-EOB-DTPA, or Gd-BOPTA showed similar0
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Figure 1. Time-enhancement changes in the livers of normal rats
or Gd-BOPTA on T1-weighted images (mean  standard deviation,enhancement patterns in the dynamic contrast study,
demonstrating rapidly increased enhancement during the
arterial phase, more intense enhancement during the
venous phase, and steady enhancement during the equi-
librium phase, as shown in Fig. 2. After 5 minutes, the liver
parenchyma of rats injected with Gd-Bz-TTDA and Gd-EOB-
DTPA showed relatively more intense enhancement than
the liver parenchyma of rats injected with Gd-BOPTA. After
30 minutes, Gd-Bz-TTDA produced more intense enhance-
ment of the liver parenchyma in normal rats than Gd-EOB-
DTPA and Gd-BOPTA (Fig. 2).
Sequential MR images of a rat with implanted HCC
before and after intravenous injection of 0.1 mmol/kg Gd-
Bz-TTDA, Gd-EOB-DTPA, and Gd-BOPTA are shown in Fig. 3.
All agents demonstrated similar enhancement patterns of
the implanted HCC, with significant enhancement of the
solid compartment of the tumor and no enhancement of
the centrally necrotic parts. These findings are consistent
with the gross pictures of the autopsy specimens and their
pathohistological features (Fig. 3D, E). After 5 minutes,60 80 100 120
 (min)
Bz-TTDA
EOB-DTPA
BOPTA
after the injection of 0.1 mmol/kg Gd-Bz-TTDA, Gd-EOB-DTPA,
n Z 12 in each group).
Figure 2. Gd-Bz-TTDA, Gd-EOB-DTPA, and Gd-BOPTA enhanced dynamic T1-weighted TFE images in normal rats. A: Precontrast
images. B: Arterial phase at 28 seconds. C: Venous phase at 70 seconds. D: Equilibrium phase at 126 seconds. E, F, G, and H:
Hepatobiliary phase at 5e120 minutes. Gd-Bz-TTDA produced more intense enhancement in liver than the other two groups at 30,
60, and 120 minutes. Circle: reference standard.
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because tumor enhancement had gradually been washed
out, but intense liver enhancement was also achieved.
After 60 minutes, liver enhancement faded in rats that
were injected with Gd-EOB-DTPA or Gd-BOPTA, whereas
intense liver enhancement persisted and good liver-lesiondiscrimination remained in rats injected with Gd-Bz-TTDA
(Fig. 3).
Quantitative analyses of the percentage increase in liver-
lesion CNR in rats with HCC after injection of Gd-Bz-TTDA,
Gd-EOB-DTPA, or Gd-BOPTA are compared in Fig. 4. Liver-
lesion CNRs were also higher in rats injected with Gd-Bz-
Figure 3. Sequential T1-weighted TFE images of a rat with implanted HCC before and after injection of 0.1 mmol/kg Gd-Bz-TTDA
(A), Gd-EOB-DTPA (B), or Gd-BOPTA (C). In the images recorded at 28 and 70 seconds, similar degrees of tumor enhancement are
noted in each group. At 5 minutes, good liver-to-lesion differentiation is demonstrated in all three groups due to the intense liver
enhancement and wash-out of the tumor contrast agent. At 60 and 120 minutes, persistent and intense liver enhancement with
better liver-lesion contrast is noted following the injection of Gd-Bz-TTDA; however, only faint enhancement of the liver and
noticeably less discrimination of the lesions are noted in the other two groups. The arrows indicate the tumor. (D) Cut surface of an
autopsied specimen with liver HCC showing central necrosis (arrow head). (E) Histological specimen demonstrating poorly
differentiated HCC, which consists of dark and light cells. Mitotic features and hypervascularity are also noted. (hematoxylin and
eosin stain, original magnification 80).
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after 30 minutes.Discussion
Gd-based hepatobiliary MR contrast agents provide the dual
benefits of dynamic contrast enhancement and delayed
hepatobiliary phase imaging [1,2]. During dynamic MR
imaging, after the bolus injection, these agents also act as
extracellular contrast agents (for example: gadopentate
dimeglumine [Gd-DTPA]) for the noninvasive detection and
characterization of liver tumors. Unlike extracellular
contrast agents, however, which rapidly leave the vascular
space and reach equilibrium with the extracellular space,providing little benefit over unenhanced images during the
equilibrium phase, hepatobiliary agents selectively accu-
mulate in the hepatocytes, leading to an increase in
contrast between the normal liver parenchyma and the
lesion [12e14]. Hepatobiliary agents are also taken up by
mass lesions with hepatocellular functions, such as regen-
erative/dysplastic nodules, focal nodular hyperplasia, and
hepatic adenoma, thus contributing to the differential
diagnosis of hepatic tumors [1,15]. Many reports have also
indicated that contrast enhancement that is induced by the
administration of hepatobiliary agents provides information
on the degree of cellular differentiation in HCC [16,17].
In this study, the liver enhancement observed in the
normal rats demonstrated similar enhancement patterns
during the arterial, venous, and equilibrium phases of the
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Figure 4. Percentage increase in liver-lesion CNR in rats with
HCC after injection of Gd-Bz-TTDA, Gd-EOB-DTPA, or Gd-
BOPTA (mean; n Z 6 in each group; solid: solid part of
tumor; necrotic: central necrotic part of the tumor).
Gd-Bz-TTDA, Gd-EOB-DTPA, BOPTA in rat liver MRI 135dynamic contrast study to the two commercialized hep-
atobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA).
Liver enhancement increased rapidly during the first
5 minutes and then reached a plateau, which slowly
decreased to 110% of enhancement at 2 hour after injec-
tion; liver enhancement of rats injected with Gd-EOB-DTPA
or Gd-BOPTA peaked at 5 minutes and then steadily
decreased. Significantly better liver enhancement
following the administration of Gd-Bz-TTDA, in comparison
with Gd-EOB-DTPA and Gd-BOPTA, was found between 10
minutes to 2 hours after injection. After 60 minutes, liver
enhancement due to these the two commercial agents was
below 50% while that of Gd-Bz-TTDA still remained above
110%. Our previous report showed that at 3 hours after
injection of Gd-Bz-TTDA, approximately 95% of enhance-
ment was preserved, which gradually declined to 15% at 24
hours [10]. This prolonged liver enhancement, which was
still apparent up to 24 hours after injection, might be of
little clinical benefit even though our preliminary subacute
toxicity study in rats showed no evidence of changes to the
liver [10].
The physicochemical characterization of Gd-Bz-TTDA
indicated a lipophilic character and weak binding to
human serum albumin, similar to Gd-EOB-DTPA [8,9].
Because of its lipophilic character and its chemical simi-
larities to Gd-EOB-DTPA, the mechanism that allows its
uptake into the liver and the biliary excretion of Gd-Bz-
TTDA may also depend on an organic anion transporter
(the same transport protein as bilirubin) that acts in the
hepatocytes [18]. Previous reports have suggested that Gd-
BOPTA is transported into rat hepatocytes via the same
pathway [19]. In a rat study, the hepatic uptake transporter
of Gd-EOB-DTPA was confirmed to be organic transporting
polypeptide (OTAP) 1 [20] and the export transporter was
confirmed as multidrug-resistant protein (MRP) 2 [21].
Recently, Kitao et al. found that enhancement of HCC in
the hepatobiliary phase of Gd-EOB-DTPA is positively
correlated with expression levels of OATP8 and MRP3 [7].
Tsuboyama et al. also confirmed that high hepatocyte-
selective enhancement is induced by the expression
patterns of these transporters, which may result in the
accumulation of Gd-EOB-DTPA in the cytoplasm of HCC cells
or in the lumina of pseudoglands [22]. Because there aresimilarities in their chemical structures, lipophilic charac-
ters, and albumin-binding characteristics of Gd-Bz-TTDA
and Gd-EOB-DTPA, the uptake and accumulation of Gd-Bz-
TTDA in HCC might also involve the above mentioned
transporters. Therefore, Gd-Bz-TTDA might play a role in
hepatocyte-specific tumor imaging. Further investigations
into the mechanisms and kinetics of Gd-Bz-TTDA in HCC
tumor cells are also required.
The better and more prolonged liver enhancement that
resulted from Gd-Bz-TTDA could be related to its higher
relaxivity and/or hepatic uptake compared with the other
two agents that were studied. The R1 relaxivity (4.9 mM-1S-1)
of Gd-Bz-TTDA is superior to Gd-BOPTA (4.39 mM-1S-1), but
slightly lower than that of GD-EOB-DTPA (5.3 mM-1S-1)
[9,23e25]. The longer rotational correlation time and faster
water-exchange lifetime also contribute to the high R1
relaxivity of Gd-Bz-TTDA [9]. The weak binding of Gd-Bz-
TTDA with serum albumin may also contribute to its plasma
T1 shortening, similar to Gd-EOB-DTPA and Gd-BOPTA
[9,24e26]. The hepatobiliary excretion of Gd-Bz-TTDA is
75.3% in rats, according to the unpublished data of our bio-
distribution study conducted using 111In. This is higher than
the values reported for Gd-EOB-DTPA (53.1e70%) and Gd-
BOPTA (38.6e50%) [25e27].
The prolonged plateau-like enhancement of Gd-Bz-TTDA
might have important practical implications because the
wide postcontrast imaging window provides flexibility for
managing patient workflow. Nevertheless, liver enhance-
ment is species specific [26e29]. In rats, up to 50% of the
Gd-BOPTA that is injected is excreted into the bile [26,27].
In contrast, in humans only 2e7% of Gd-BOPTA is excreted
into the bile [26,28]. Up to 70% of Gd-EOB-DTPA is excreted
into the bile in rats and up to 50% is excreted into the bile in
humans [1,29]. Liver enhancement and biliary excretion of
Gd-Bz-TTDA in humans require further evaluation. Liver
enhancement of Gd-based hepatobiliary contrast agents is
dose-related [25]. The clinical recommended dose of Gd-
EOB-DTPA is 0.025 mmol/kg and that of Gd-BOPTA is
0.1 mmol/kg. Therefore, the results of the liver enhance-
ment studies in this rat model cannot be directly applied to
clinical situations. Further clinical trials are required.
In the MR imaging study of rats with implanted HCC, all
three hepatobiliary agents demonstrated dynamic
enhancement capabilities for hepatic tumors, similar to the
extracellular agents. Liver-lesion discrimination was
significantly enhanced during the hepatobiliary phase for
all three agents. Nevertheless, the liver-lesion CNRs were
higher in rats injected with Gd-Bz-TTDA than the other two
groups due to more intense and prolonged liver enhance-
ment. A previous toxicity study on Gd-Bz-TTDA revealed no
changes in liver or kidney tissues when the animals were
sacrificed at 14 days postinjection [10]. The LD50 (Lethal
Dose, 50%) of Gd-Bz-TTDA in mice is 7.5 mmol/kg [10]. This
value is comparable with the LD50 of Gd-EOB-DTPA, which
ranges from 7.5e10 mmol/kg, and that of Gd-BOPTA, which
ranges from 5.7e7.9 mmol/kg [25,29,30]. Toxicity studies
on Gd-BOPTA and Gd-EOB-DTPA performed on animals have
shown good neural and cardiovascular tolerabilities for
these lipophilic contrast agents [25,31]. Nevertheless,
cardiovascular and neurological adverse reactions could
still occur in a clinical setting. [32,33]. The prolonged
retention of Gd-Bz-TTDA in the body might raise concerns
136 T.-S. Jaw et al.about the increased risk of the side effects that are induced
by Gd-chelated contrast agents, such as nephrogenic
systemic fibrosis or cardiovascular or neural adverse reac-
tions [32e34]. Therefore, further safety and pharmacology
studies on Gd-Bz-TTDA will be required.
In conclusion, the results of this study indicate that Gd-
Bz-TTDA is comparable with the commercially available
hepatobiliary MR contrast agents, Gd-BOPTA and Gd-EOB-
DTPA, but is characterized by more intense and prolonged
liver enhancement and better liver-lesion discrimination.
Therefore, further large-scale studies are warranted.
Acknowledgments
We are grateful to the National Science Council of Taiwan
ROC for their financial support (NSC 93-2314-B-037-068).
References
[1] Seale MK, Catalano OA, Saini S, Hahn PF, Vahani DV. Hep-
atobiliary-specific MR contrast agents: role in imaging the liver
and biliary tree. Radiographics 2009;29:1725e48.
[2] Semlka RC, Helmberger TK. Contrast agents for MR imaging of
the liver. Radiology 2001;218:27e38.
[3] Ku¨hn JP, Hegenscheid K, Seigmund W, Froehlich CP, Hosten N,
Puls R. Normal dynamic MRI enhancement patterns of the
upper abdominal organs: gadoxetic acid compared with
gadobutrol. AJR Am J Roentgenol 2009;193:1318e23.
[4] Ba-Ssalamah A, Uffmann M, Saini S, Bastati N, Herold C,
Schima W. Clinical value of MRI liver-specific contrast agents:
a tailored examination for a confident non-invasive diagnosis
of focal liver lesions. Eur Radiol 2009;19:342e57.
[5] Ahn SS, Kim MJ, Js Lim, Hong HS, Chung YE, Choi JY. Added
value of gadoxetic acid-enhanced hepatobiliary phase MR
imaging in the diagnosis of hepatocellular carcinoma. Radi-
ology 2010;255:459e66.
[6] Hwang HS, Kim SH, Jeon TY, Choi DC, Lee WJ, Lim KH.
Hypointense hepatic lesions depicted on gadobenate dime-
glumine three-hour delayed hepatobiliary-phase MR imaging:
differentiation between benignancy and malignancy. Korea J
Radiol 2009;10:294e302.
[7] Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, et al.
Hepatocellular carcinoma: Signal intensity at gadoxetic acid-
enhanced MR imaging; correlation with molecular transports
and histopathologic features. Radiology 2010;256:817e26.
[8] Wang YM, Lee CH, Liu GC, Sheu RS. Synthesis and complexation
of Gd3þ, Ca2þ, Cu2þ, and Zn2þ by 3,6, 10-tri(carboxymethyl)-
3,6,10-triazadodeanedioic acid. JChemSocDaltonTrans; 1998:
4113e8.
[9] Cheng TH, Lee TM, Ou MH, Li CR, Liu GC, Wang YM. Thermo-
dynamic stability and physicochemical characterization
of ligand (4S)-4-benzyl-3,6-10-tris(carboxymethyl)- 3,6,10-
trizadodecanedioic acid (H5-[(s)-4-Bz-TTDA]) and its
complexes formed with lanthanides, calcium (II), zinc(II), and
copper (II) ions. Helv Chim Acta 2002;85:1033e50.
[10] Hsu FS, Jaw TS, Liu GC, Wang YM, Chen SH, Kuo YT, et al.
Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in
MR imaging of the hepatobiliary system: an animal study. J
Magn Reson Imaging 2004;20:632e9.
[11] Smith DF, Walborg Jr EF, Chang JP. Establishment of a trans-
plantable ascites variant of a rat hepatoma induced by 3’-
methyl-4-dimethylaminoazobenene. Cancer Res 1970;30:
2306e9.
[12] Caudana R, Morana G, Pirovan GP, Nicoli N, Portuese A,
Spinazzi A, et al. Focal malignant hepatic lesions: MR imagingenhanced with gadolinium benzyloxylpropionic tetra-acetate
(BOPTA); preliminary results of phase II clinical application.
Radiology 1996;199:513e20.
[13] Torres CG, Lundy B, Sterud AT, McGill S, Gordo PB,
Bjerknes HS. Mn-DPDP for MR imaging of the liver: results from
the European phase III studies. Acad Radiol 1997;38:631e7.
[14] Vogl TJ, Kummel S, Hammerstingl R, Schellenbeck M,
Schumacher G, Balzer T, et al. Liver tumors: comparison of MR
imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200:
59e67.
[15] Grazioli L, Morana G, Federle MP, Brancatelli G, Testoni M,
Kirchin MA, et al. Focal nodular hyperplasia: Morphologic and
functional information from MR imaging with gadobenate
dimeglumine. Radiology 2001;221:731e9.
[16] Ni Y, Marchal G, Yu J, Mu¨hler A, Lukito G, Baert AL. Prolonged
positive contrast enhancement with Gd-EDB-DTPA in experi-
mental liver tumors: potential value in tissue characteriza-
tion. J Magn Reson Imaging 1994;4:353e63.
[17] Manfredi R, Maresca G, Baron RL, Cotroneo AR, De
Gaetano AM, De Franco A, et al. Delayed MR imaging of
hepatocellular carcinoma enhanced by gadobenate dimeglu-
mine (Gd-BOPTA). J Magn Reson Imaging 1999;9:704e10.
[18] Ni Y, Marchal G, Lukito G, Yu J, Mu¨hler A, Baert AL. MR imaging
evaluation of liver enhancement by Gd-EOB-DTPA in selective
and total bile duct obstruction in rats: correlation with sero-
logic, microcholangiographic, and histologic findings. Radi-
ology 1994;190:753e8.
[19] Planchang C, Gex-Fabry M, Dornier C, Quadri R, Resit M,
Invancevic K, et al. Gd-BOPTA transport into rat hepatocytes:
pharmacokinetic analysis of dynamic magnetic resonance
images using a hollow-fiber bioreactor. Invest Radiol 2004;39:
506e16.
[20] Van Montfort JE, Stieger B, Meijer DK, Weinmann HJ,
Meier PJ, Fattinger KE. Hepatic uptake of magnetic resonance
imaging contrast agent gadoxetate by the organic transporting
polypeptide Oatp l. J Pharmaco Ther 1999;290(1):153e7.
[21] Tsuboyana T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, et al.
Hepatocellular carcinoma: hepatocyte-selective enhance-
ment at gadoxetic acid-enhanced MR imagingecorrelation
with expression of sinusoidal and canalicular transporters and
bile accumulation. Radiology 2010;255:824e33.
[22] Lorusso V, Pascolo L, Fernetti C, Visigalli M, Anelli P,
Tiribelli C. In vitro and in vivo hepatic transport of the
magnetic resonance imaging contrast agent B22956/1: Role
of MRP proteins. Biochem Biophys Res Commun 2002;293:
100e5.
[23] Uggeri F, Aime S, Anelli PL, Botta M, Brochetia M, Haen C,
et al. Novel contrast agents for magnetic resonance imaging
synthesis and characterization of the ligand BOPTA and its
Ln(III) complexes (Ln Z Gd, Ld, Lu). X-ray structure of diso-
dium (TPS-9-145337286-C-S)-[4-carboxyl-5,8,11-tris (carbox-
ymethyl)-1-phenyl-2-oxa- 5,8,11-triazatridecan-13-oato(5-)
gadolinite(2-) in a mixture with its enantiomer. Inog Chem
1995;34:633e42.
[24] Pintaske J, Martirosian P, Gra SH, Erb G, Lodeman KP,
Claussen CD, et al. Relaxivity of gadopentetate dimeglumine
(Magnevist), gadobutrol (Gadovist) and gadobenate dimeglu-
mine (MultiHance) in human blood plasma at 0.2, 1.5 and 5
Teslar. Invest Radiol 2006;41:213e21.
[25] Schuhmann-Giampierir G, Schmitt-Willich H, Press WR,
Negishi C, Weinmann H-J, Speck U. Preclinical evaluation of
Gd-EOB-DTPA as a contrast agent in MR imaging of the hep-
atobiliary system. Radiology 1992;183:59e64.
[26] Lorusso V, Tiziano A, Trione P, de Haeˆn C. Pharmacokinetics
and tissue distribution in animals of gadobenate ion, the
magnetic resonance imaging contrast enhancing component
of gadobenate dimeglumine 0.5 M solution for injection
(MultiHance). J Comput Assist Tomogr 1999;23:S181e94.
Gd-Bz-TTDA, Gd-EOB-DTPA, BOPTA in rat liver MRI 137[27] DeHae¨n C, LorussoV, TironeP.Hepatic transport of gadobenate
dimeglumine in TR rats. Acad Radiol 1996;3:452e4.
[28] Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M,
Davies A. MultiHance clinical pharmacology. Acad Radiol 1998;
5(Suppl.):86e9.
[29] Weinmann HJ, Schuhmann-Giampiepi G, Schmitt-Willich H,
Vogler H, Frenzei Gries H. A new lipophilic gadolinium chelate
as a tissue-specific contrast medium for MRI. Magn Reson Med
1991;22:233e7.
[30] Morisetti A, Bussi S, Tirone P, de Haenn C. Toxicological
safety evaluation of gadobenate dimeglumine 0.5 M solution
for injection (MultiHance): a new magnetic resonance
imaging contrast medium. J Comput Assist Tomogr 1999;23:
S207e17.[31] Tirone P, Castano M, Cipolla P, Frigeni V, Noce AL, Luzzani F,
et al. General pharmacology in experimental animals of
gadobenate dimeglumine (MultiHance): a new magnetic
resonance imaging contrast agent. J Comput Assist Tomogr
1999;23:S195e206.
[32] Abujudeh HH, Kosaraju VK, Kaewlai R. Acute adverse reactions
to gadopentetate dimeglumine and gadobenate dimeglumine:
experience with 32,659 injections. AJR 2010;194:430e4.
[33] Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J,
Brown JT, et al. Efficacy and safety of MR imaging with liver-
specific contrast agent: US multicenter phase III study. Radi-
ology 2005;237:89e98.
[34] Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-
based contrast agent. Adv Chronic Kidney Dis 2011;18:188e98.
